Cullinan Oncology Inc. (CGEM)
NASDAQ: CGEM
· Real-Time Price · USD
8.29
-0.50 (-5.69%)
At close: May 05, 2025, 3:59 PM
8.27
-0.24%
After-hours: May 05, 2025, 04:43 PM EDT
-5.69% (1D)
| Bid | 8 |
| Market Cap | 489.23M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -167.38M |
| EPS (ttm) | -2.78 |
| PE Ratio (ttm) | -2.98 |
| Forward PE | -2.83 |
| Analyst | Buy |
| Ask | 9 |
| Volume | 278,073 |
| Avg. Volume (20D) | 459,373 |
| Open | 8.66 |
| Previous Close | 8.79 |
| Day's Range | 8.27 - 8.71 |
| 52-Week Range | 6.85 - 30.19 |
| Beta | -0.07 |
About CGEM
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody f...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 8, 2021
Employees 111
Stock Exchange NASDAQ
Ticker Symbol CGEM
Website https://www.cullinanoncology.com
Analyst Forecast
According to 4 analyst ratings, the average rating for CGEM stock is "Buy." The 12-month stock price forecast is $34, which is an increase of 310.13% from the latest price.
Stock Forecasts3 months ago
+7.66%
Cullinan Therapeutics shares are trading higher af...
Unlock content with
Pro Subscription
6 months ago
+8.44%
Cullinan Therapeutics shares are trading higher after the FDA cleared the company's IND application for CLN-978.
